The Association of Chronic Lung Disease With Early Mortality and Respiratory Adverse Events After Aortic Valve Replacement Juan A. Crestanello, MD, Robert S.D. Higgins, MD, Xia He, MS, Paramita Saha-Chaudhuri, PhD, Brian R. Englum, MD, J. Matthew Brennan, MD, MPH, Vinod H. Thourani, MD The Annals of Thoracic Surgery Volume 98, Issue 6, Pages 2068-2077 (December 2014) DOI: 10.1016/j.athoracsur.2014.06.087 Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Flow diagram of patients included in the primary and secondary analyses. (ABG = arterial blood gases; AVR = aortic valve replacement; CLD = chronic lung disease; DLCO = diffusion capacity of the lung for carbon monoxide; FEV1 = forced expiratory volume in 1 second; PaCO2 = arterial carbon dioxide tension; PaO2 = arterial oxygen tension; PFT = pulmonary function tests.) The Annals of Thoracic Surgery 2014 98, 2068-2077DOI: (10.1016/j.athoracsur.2014.06.087) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 (A) Unadjusted and multivariable risk-adjusted mortality, (B) pulmonary morbidity, and (C) prolonged length of hospital stay stratified by the severity of chronic lung disease (CLD). Prevalence is displayed as a percentage (bars, p < 0.0001). Odds ratios (OR) are displayed as point estimates (circles) and 95% confidence intervals (CI) (error bars). The Annals of Thoracic Surgery 2014 98, 2068-2077DOI: (10.1016/j.athoracsur.2014.06.087) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions